Aberrant methylation of Reprimo in human malignancies

International Journal of Cancer

Volumn 115, Issue 4, 2005, Pages 503-510

  Takahashi, Takao ^a,b   Suzuki, Makoto ^a   Shigematsu, Hisayuki ^a   Shivapurkar, Narayan ^a,c   Echebiri, Chinyere ^a   Nomura, Masaharu ^a   Stastny, Victor ^a   Augustus, Meena ^d   Wu, Chew Wun ^e   Wistuba, Ignacio I ^f,g   Meltzer, Stephen J ^h   Gazdar, Adi F ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Avalon Pharmaceuticals   (United States)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Human cancer; Methylation; Reprimo

Indexed keywords

GLYCOSYLATED PROTEIN; PROTEIN P53; REPRIMO; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CELL CULTURE; CELL CYCLE G2 PHASE; COLORECTAL CANCER; DATA ANALYSIS; DNA EXTRACTION; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; GALLBLADDER CANCER; GENE EXPRESSION; GENE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MEDIATOR; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH EPITHELIUM; TUMOR; TUMOR CELL LINE; UTERINE CERVIX CANCER;

ADULT; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHILD; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; NEOPLASMS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 20844443467     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20910     Document Type: Article

References (30)

1. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
2. Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S, Yokota J. Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer 1996;16:113-9.
3. Olaru A, Mori Y, Yin J, Wang S, Kimos MC, Perry K, Xu Y, Sato F, Selaru FM, Deacu E, Sterian A, Shibata D, et al. Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors. Lab Invest 2003;83:1867-71.
4. Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2001;30:113-22.
5. 2 phase. J Biol Chem 2000;275:22627-30.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
7. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
8. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
10. Suzuki M, Shigematsu H, Takahashi T, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Gazdar AF. Aberrant methylation of Reprimo in lung cancer. Lung Cancer, in press.
11. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998;78:766-74.
12. Toyooka S, Fukuyama Y, Wistuba II, Tockman MS, Minna JD, Gazdar AF. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 2002;8:2292-7.
13. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61:4556-60.
14. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-63.
15. Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zochbauer-Muller S, Drach J, Parikh G, Zheng Y, Feng Z, et al. DNA methylation profiles of lymphoid and hemaoietic malignancies. Clin Cancer Res 2004;10:2928-35.
16. Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO, Gilcrease M, Farinas A, Minna JD, Gazdar AF. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30.
17. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD, Gazdar AF. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-9.
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
19. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002;21:2328-33.
20. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 1999;18:7883-99.
21. 2/M transition by p53. Oncogene 2001;20:1803-15.
22. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3σ gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000;60:4353-7.
23. Zhang Z, Li J, Lantry LE, Wang Y, Wiseman RW, Lubet RA, You M. p53 transgenic mice are highly susceptible to 1,2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002;62:3024-9.
24. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
25. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
26. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003;163:1551-6.
27. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002;161:399-403.
28. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nature Rev Cancer 2004;4:695-706.
29. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003;100:7818-23.
30. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003;24:47-51.